Anjali Pandey is an executive leader with 25+ years of experience in CSO/SVP roles through all stages of discovery, development through launch. Anjali previously served as SVP of Medicinal Chemistry & Chemical Development at Portola Pharmaceuticals, where she managed discovery and chemistry, manufacturing and control (CMC) function for Bevyxxa™, Cerdulatinib and all the other small molecule programs. Anjali was responsible for the technical and management leadership of medicinal chemistry team to discover novel small molecule inhibitors for oncology, inflammation and cardiovascular programs at Portola. Anjali has been significant contributor towards discovery, development and IND-ready and/or 1st in human study for 13 compounds. Anjali led the development and management of Portola Pharma’s intellectual property portfolio. Most recently, Anjali held CSO/EVP positions at BridgeBio Pharma subsidiaries TheRas, Inc. and Ferro Therapeutics. In CSO role built the teams, directed research and development activities for Oncology programs. Dr. Pandey has published 45+ scientific publications and is inventor on 60 issued U.S. patents. She holds an MS from the Indian Institute of Technology, Kanpur and a PhD from Southern Illinois University, and completed her postdoctoral fellowship at SRI International.